BioAge Labs, Inc.

As of June 30, 2026, BioAge Labs, Inc. carries a market capitalization of 986.03M, placing it among publicly traded companies globally. Its enterprise value stands at 709.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioAge Labs, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, BioAge Labs, Inc. has 45.78M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 94.63, and the price-to-book ratio stands at 3.00.

These figures are as of June 30, 2026. The EV/Sales ratio of 78.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 709.52M versus a market cap of 986.03M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioAge Labs, Inc. maintains a current ratio of 17.19, meaning it holds 17.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.76, indicating moderate leverage, while an interest coverage ratio of -377.30 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioAge Labs, Inc. posted a negative return on equity (ROE) of -28.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -26.27, reflecting losses generated across the asset base. The company generates approximately 145,019.70 in revenue per employee across its workforce of 62.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, BioAge Labs, Inc.'s stock has declined approximately 7.43% over the past 52 weeks. The 50-day moving average sits at 6.93, while the 200-day moving average is 13.98.

Over the twelve months ended June 30, 2026, BioAge Labs, Inc. generated 9.06M in revenue and converted that into -82.68M in net income, yielding earnings per share of -2.08. EBITDA reached -92.80M, while operating income came in at -93.02M.

As of June 30, 2026, BioAge Labs, Inc. holds 279.00M in cash and equivalents against 2.48M in total debt, resulting in a net debt position of -64.74M. Total book value stands at 328.16M, with working capital of 272.30M providing operational flexibility.

BioAge Labs, Inc. produced -76.68M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -427,146.40 in capital expenditures, free cash flow totaled -77.10M - equivalent to -1.94 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,026.28 and net profit margin of -912.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.68, meaning BioAge Labs, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BioAge Labs, Inc. has an Altman Z-Score of 29.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.